The report "Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021" The Cancer Immunotherapy Market Is Expected to Reach USD 119.39 Billion by 2021. Report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the Cancer Immunotherapy market along with the estimates and forecasts of the revenue and market share analysis.
Browse 42 market data Tables and 68 Figures spread through 140 Pages and in-depth TOC on "Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021"
View detailed Table of Content here -https://www.marketsandmarkets.com/Market-Reports/cancer-immunotherapy-market-197577894.html
The monoclonal antibody segment is expected to lead the global cancer immunotherapy market during the forecast period
Monoclonal antibodies are emerging as the most effective therapeutic agents for the treatment of malignancy. They are currently one of the largest classes of agents approved for the treatment of cancer. Several antibodies are widely adopted, owing to their lesser side effects as compared to chemotherapy. Antibodies are developed to treat several cancers such as lymphoma, leukemia, melanoma, breast cancer, and lung cancer. Cancer monoclonal antibodies are sub-segmented into naked monoclonal antibodies, conjugated monoclonal antibodies, and bispecific monoclonal antibodies.
The Lung Cancer application segment is expected to grow at a high CAGR during the forecast period
The current immunotherapies for lung cancer treatment, such as checkpoint inhibitors, monoclonal antibodies, therapeutic vaccines, and other cell therapies, have benefited some patients with advanced lung cancer in the form of durable remission and prolonged survival. The Lung Cancer segment is expected to grow at a high CAGR from 2016 to 2021, owing to the increase in prevalence, patient pool urges a demand for advanced treatment options, and this increases the growth of Cancer Immunotherapy market.
The hospitals end user segment is expected to account for the largest share of the global Cancer Immunotherapy market
End-users, included in the Cancer Immunotherapy market are hospitals, clinics and others. The hospitals segment of the global cancer immunotherapy market includes private hospitals and public hospitals. The hospitals segment is expected to account for the largest share of the global Cancer Immunotherapy market in 2016. Rise in healthcare spending has resulted in the increasing use of immuno therapeutic drugs in hospitals and clinics.
North America is expected to account for the largest share of the market during the forecast period
Based on regions, the global Cancer Immunotherapy market is segmented into North America, APAC, Europe and the Rest of the World (RoW). North America is expected to account for the largest share of the market during the forecast period. Growth in this regional segment is driven by factors such as increase in patient pool, and initiative taken by the government for the development of Cancer Immunotherapy.
Key players in the Cancer Immunotherapy market include Amgen (US), AstraZeneca (UK), F.Hoffman La Roche (Switzerland), BayerAG (Germany), Bristol-myers squibb(US), Eli Lilly and Company (US), Janssen Global Services, LLC (Belgium), Merck (US), Novartis (Switzerland), Pfizer (US)
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Shelly Singh
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441